Background
Skin suffers progressive decrement. An endogenous regenerative technology has been developed that has the versatility to provide an autologous injectable gel (Endoret‐Gel) or a liquid plasma rich in growth factors (PRGF) based on the patient´s own platelet‐rich plasma.
Aims
To compare the efficacy of the combined therapy with Endoret‐Gel and PRGF versus Endoret‐Gel alone in the management of facial rejuvenation.
Methods
Twenty clinically diagnosed patients with aged skin received either Endoret‐Gel monotherapy or Endoret‐Gel + PRGF combined therapy. Patients underwent three sessions at one‐month intervals and were clinically assessed for six months. Corneometry, sebumetry, and high‐resolution topographic analysis were carried out. Patient self‐assessment questionnaires and clinical improvement scores were also performed.
Results
The combined therapy showed to promote a higher hydration index. These results were also significant for spot improvement at three months, while conversely, monotherapy with Endoret‐Gel demonstrated higher UV spot improvement. A significant decrease of sebum production and wrinkle development was observed for both treatment groups. Red areas also improved in a similar way at the end of the follow‐up period. After Endoret‐Gel or Endoret‐Gel + PRGF therapy, 30% and 70% of patients referred to be very satisfied, respectively. Accordingly, 40% and 80% showed a “very improved” esthetic performance. None of the patients reported a negative change and no adverse events were recorded.
Conclusion
Both Endoret‐Gel monotherapy and the combined treatment with PRGF were shown to promote facial rejuvenation and to palliate the age‐related cutaneous atrophy. The combined therapy may exert a synergistic effect that addresses both skin quality improvement and soft tissue restoration in a shorter period.